Melinta Therapeutics Reports Fourth Quarter and Full-Year 2018 Financial Results
March 13, 2019 16:00 ET
|
Melinta Therapeutics
~ Reports Revenue of $96.4 million, Including Net Product Sales of $46.6 million, for the Full-Year 2018 ~ ~ Net Product Sales of $14.6 million for the Fourth Quarter of 2018, up 32 Percent from...
Melinta Therapeutics to Report Fourth Quarter and Year-End 2018 Financial Results on March 13, 2019
March 05, 2019 08:00 ET
|
Melinta Therapeutics
MORRISTOWN, N.J., March 05, 2019 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company focused on the development and commercialization of novel antibiotics to...
Melinta Therapeutics Announces Closing of Initial $75 Million Vatera Convertible Loan Funding
February 25, 2019 08:15 ET
|
Melinta Therapeutics
– Amendment to Deerfield Facility Agreement Becomes Effective – – John H. Johnson Appointed Permanent Chief Executive Officer – – Company to Report Fourth Quarter and Full Year 2018 Financial...
Summit’s SMT-571 Potent Against Over 200 Clinical Isolates of Neisseria Gonorrhoeae, Including Numerous Multi- and Extensively-Drug Resistant Strains, in Published Preclinical Data
February 25, 2019 07:00 ET
|
Summit Therapeutics plc
Summit Therapeutics plc (‘Summit’ or the ’Company’) Summit’s SMT-571 Potent Against Over 200 Clinical Isolates of Neisseria Gonorrhoeae, Including Numerous Multi- and Extensively-Drug Resistant...
9 impressive research efforts underway in Wisconsin
January 10, 2019 08:30 ET
|
Concordia University Wisconsin
Mequon, Jan. 10, 2019 (GLOBE NEWSWIRE) -- With China’s historic moon landing last week and the 50th anniversary of Apollo 11 approaching this summer, 2019 is shaping up to be an exciting year for...
Completion of $25 million subscription
January 10, 2019 07:00 ET
|
Summit Therapeutics plc
Summit Therapeutics plc(“Summit Therapeutics” or the “Company”) Completion of $25 million subscription Oxford, UK, and Cambridge, MA, US, 10 January 2019 - Summit Therapeutics (AIM: SUMM, NASDAQ:...
Completion of $25 million Subscription
January 10, 2019 02:00 ET
|
Summit Therapeutics plc
Summit Therapeutics plc(“Summit Therapeutics” or the “Company”) Completion of $25 million subscription Oxford, UK, and Cambridge, MA, US, 10 January 2019 - Summit Therapeutics (AIM: SUMM,...
Fedora Pharmaceuticals and Meiji Seika Pharma Sign Basic Agreement to Establish NacuGen Therapeutics Inc., a Joint Venture to Develop and Commercialize Nacubactam for Bacterial Infections
January 07, 2019 09:00 ET
|
Nacugen Therapeutics, Inc.
EDMONTON, Alberta and Tokyo , Jan. 07, 2019 (GLOBE NEWSWIRE) -- Fedora Pharmaceuticals, Inc. (headquarters: Edmonton, Alberta, Canada; Chief Executive Officer: Christopher G. Micetich, hereinafter...
Global charity discovers superbugs in pork products
December 19, 2018 08:00 ET
|
World Animal Protection
Toronto, ON, Dec. 19, 2018 (GLOBE NEWSWIRE) -- Bacteria that is resistant to antibiotics most critically important to humans, has been found in pork from supermarket shelves in Brazil, Spain and...
Proposed Subscription to Raise $25m and Notice of General Meeting
December 17, 2018 02:05 ET
|
Summit Therapeutics plc
THIS ANNOUNCEMENT (INCLUDING THE APPENDICES) AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, OR...